Grace Therapeutics, Inc. GRCE · Stock Open Grace Therapeutics, Inc. in new tab

2.22 USD

Add to portfolio

EPS

-0.31

P/B

0.64

ROE

-10.22

Beta

0.32

Target Price

5.93 USD

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Grace Therapeutics, Inc. (GRCE)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Grace Therapeutics, Inc. Analysis (GRCE)

Official Website Stock

Is Grace Therapeutics, Inc. a good investment? Grace Therapeutics, Inc. (GRCE) is currently trading at 2.22 USD. Market analysts have a consensus price target of 5.93 USD. This suggests a potential upside from current levels.

Earnings Schedule: Grace Therapeutics, Inc. is expected to release its next earnings report on June 22, 2026. The market consensus estimate for Forward EPS is -0.69.

Investor FAQ

Does Grace Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Grace Therapeutics, Inc.?

Grace Therapeutics, Inc. is classified as a Stock.

When is the next earnings date?

The next earnings date is projected to be June 22, 2026. The company currently has a trailing EPS of -0.31.

Company Profile

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Trades

Dividend History paid per year (USD)

No dividend history available.

Stock Splits

Split Date	Split Ratio to 1
Oct. 15, 2015	0.100000
Aug. 31, 2021	0.125000
July 10, 2023	0.166667
July 10, 2023	0.170000
Aug. 31, 2021	0.120000

Fundamentals

2026 © AllInvestView

Twitter YouTube Reddit Feature Requests Support Pricing Help

Support email: [email protected]

Terms of Service | Privacy Policy

Free Trackers · Dividend Apps · Tax Reporting · UK · Australia · Germany · Guides · Ticker Logos

Stock Directory · Financial Glossary · Portfolio Templates · Top Dividend Stocks · Investing in US · Investing in UK · Import Guides · Stock Comparison · Earnings Recaps

Data disclaimer: AIV (AllInvestView) assumes no liability for the information presented. Users are encouraged to exercise caution and carefully consider the accuracy, completeness, and relevance of the information provided.

It's important to remember that our website should complement your independent market research rather than replace it. The past performance of assets should not be regarded as a guarantee of future results. AllInvestView is not a registered investment advisor or broker/dealer, and the information presented here is for educational and informational purposes only. We value your trust and are committed to providing you with valuable market insights while emphasizing the importance of responsible decision-making in your investment journey.